

IFW

## CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers Date: JUNE 21, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Information Disclosure Statement</b>  <b>Address to:</b> <b>Commissioner of Patents</b> <b>PO Box 1450</b> <b>Alexandria, VA 22313-1450</b>	<b>First Named Inventor</b>	<b>James Patrick Dunn</b>
	<b>Application Number</b>	<b>10/807,993</b>
	<b>Filing Date</b>	<b>March 23, 2004</b>
	<b>Group Art Unit</b>	<b>1624</b>
	<b>Examiner</b>	<b>unassigned</b>
	<b>Attorney Docket No.</b>	<b>R0169B-REG</b>
	<b>Title</b>	<b>Non-Nucleoside Reverse Transcriptase Inhibitors</b>


Sir:

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.56, which may be material to the patentability of the subject patent application.

- [X] Attached are:
- Form 1449, "List of References Cited," with copies of references B1-B5 and C1-C3
  - Return postcard
- [X] The Information Disclosure Statement is being submitted (a) within three months of the filing date, and (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- [X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Brian L. Buckwalter", written in a cursive style.

Brian L. Buckwalter

Reg. No. 46,585

Agent for Applicants

Roche Bioscience  
Patent Law Dept.  
3431 Hillview Avenue - M/S A2-250  
Palo Alto, CA 94304  
Direct Phone (650) 855-5311

Date: June 21, 2004



IDS No. 1	<b><u>LIST OF REFERENCE(S) CITED</u></b>	Atty. Docket No. R-0169B-REG	Serial No. 10/807,993
		Applicants James Dunn, <i>et al.</i>	
		Filing Date March 23, 2004	Group 1624

#### U.S. PATENT DOCUMENTS

Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date
	A1	5,886,178	03/23/1999	Darin A. Allen, <i>et al.</i>		

#### FOREIGN PATENT DOCUMENTS

	Ref.#	Document #	Publication Date	Country; Assignee	Language
	B1	WO 96/24343-A1	08-15-1996	PCT, Smithkline Beecham Corp., U.S.	
	B2	WO 96/34851-A1	11-07-1996	PCT, Abbott Laboratories, U.S.	
	B3	WO 97/02023-A1	01-23-1997	PCT, Smithkline Beecham Corp., U.S.	
	B4	WO 97/02024-A1	01-23-1997	PCT, Smithkline Beecham Corp., U.S.	
	B5	WO 01/85670-A1	11-15-2001	PCT, Kissei Pharmaceutical Co., Ltd. (In Japanese w/ English Abstract)	

#### OTHER DOCUMENTS

	C1	De CLERCQ, Erik, "New Developments in Anti-HIV Chemotherapy," <i>Current Medicinal Chemistry</i> , 2001, pp 1543-1572, vol. 8. No. 13.
	C2	LEESON, Paul D., "Selective Thyromimetics. Cardiac-Sparing Thyroid Hormone Analogues Containing 3'-Arylmethyl Substituents," <i>J. Med. Chem.</i> , 1989, pp. 320-336, vol. 32, no.2.
	C3	BUCKHEIT, Jr., Robert W., "Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection," <i>Expert Opin. Investig. Drugs</i> , Ashley Publications Ltd., 2001, pp. 1423-1442, vol. 10, no. 8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.